Evidence map›Paper›PMID 39070198›Full record

ArticleBasic and clinical neuroscience

Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs.

Maryam Salehbayat, Roya Abolfazli, Niayesh Mohebbi, Seyed Mehrdad Savar, Gloria Shalviri, Kheirollah Gholami

Abstract read
In one paragraph

Article in Basic and clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maryam SalehbayatSchool of Pharmacy, International Campus, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-0341-4527
Roya AbolfazliDepartment of Neurology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-3506-7200
Niayesh MohebbiDepartment of Clinical Pharmacy, Rational Use of Drugs Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1420-7286
Seyed Mehrdad SavarResearch Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-9744-9362
Gloria ShalviriResearch Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-3155-3439
Kheirollah GholamiDepartment of Clinical Pharmacy, Rational Use of Drugs Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-1340-8454

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study. Methods: ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated. Results: A total of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious. Conclusion: The high frequency of adverse drug reactions in this study shows a strong need for strategy planning to increase patients' adherence to treatment. Highlights: Adverse drug reactions (ADRs) are common in MS patients using disease modifying therapies.Such ADRs are more common in women than men.Various brand names of biosimilar disease-modifying therapy (DMT)s may have a different ADR profile. Plain Language Summary: Multiple sclerosis (MS) is a condition that can be managed by using disease modifying medications. Such medication could trigger an adverse reaction in the patients., affecting their commitment to the treatment. By identifying these adverse reactions and educating the MS patients about these reactions and how the adverse effects can be managed, healthcare providers can improve the treatment process. This study recorded the adverse drug reactions in 250 MS patients who were receiving the medication for at least three months. Most of the patients (76.4%) experienced some kind of adverse reaction. A bigger proportion of women experienced adverse reactions than men. About 84% of these reactions occurred within the first 3 hours of receiving the medication. Depending on the medication's brand name, the rate of adverse drug reactions were different in some cases. The results of this study point out the fact that experiencing adverse drug reactions is common in MS patients and these experiences could be different for each medication with a different brand name. Therefore, it is important for the healthcare providers to inform the patients about such reactions and the patients should seek all the information they need to manage these adverse effects by consulting their physician.

Indexed as

Adverse drug reactionsComplianceInterferonsNeurologyNeuropharmacology

Identifiers

PMID39070198
PMCPMC11273197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.